Literature DB >> 23278586

Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.

Jaap J Plomp1, Maartje G Huijbers, Silvère M van der Maarel, Jan J Verschuuren.   

Abstract

Autoantibodies against muscle-specific kinase (MuSK), a protein essential for clustering of acetylcholine receptors at the neuromuscular junction (NMJ), are detected in the serum of a proportion of myasthenia gravis (MG) patients. In most MuSK MG patients the anti-MuSK activity resides in the IgG4 subclass, a minor IgG component without very well-defined, but presumably anti-inflammatory, roles in immunity. In recent years, several animal model studies showed that anti-MuSK autoantibodies can cause muscle weakness by directly affecting NMJ function and, therefore, are likely not simply bystander disease markers in MuSK MG patients. In passive transfer mice, we recently provided proof that MuSK MG patient IgG4 is severely myasthenogenic, causing functional defects at NMJs. Against the clinical, serological, and pharmacological background of MuSK MG, here we discuss the MuSK MG animal models generated by our laboratory and others that have been instrumental in elucidating the etiological and pathophysiological roles of anti-MuSK antibodies.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23278586     DOI: 10.1111/j.1749-6632.2012.06808.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

Review 1.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

Review 2.  Myasthenia gravis - autoantibody characteristics and their implications for therapy.

Authors:  Nils Erik Gilhus; Geir Olve Skeie; Fredrik Romi; Konstantinos Lazaridis; Paraskevi Zisimopoulou; Socrates Tzartos
Journal:  Nat Rev Neurol       Date:  2016-04-22       Impact factor: 42.937

Review 3.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

4.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

Review 5.  IgG4-related disease and its pathogenesis-cross-talk between innate and acquired immunity.

Authors:  Hisanori Umehara; Akio Nakajima; Takuji Nakamura; Takafumi Kawanami; Masao Tanaka; Lingli Dong; Mitsuhiro Kawano
Journal:  Int Immunol       Date:  2014-07-14       Impact factor: 4.823

6.  Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features.

Authors:  Kee Hong Park; Patrick Waters; Mark Woodhall; Bethan Lang; Thomas Smith; Jung-Joon Sung; Kwang-Kuk Kim; Young-Min Lim; Jee-Eun Kim; Byung-Jo Kim; Jin-Sung Park; Jeong-Geon Lim; Dae-Seong Kim; Ohyun Kwon; Eun Hee Sohn; Jong Seok Bae; Byung-Nam Yoon; Nam-Hee Kim; Suk-Won Ahn; Jeeyoung Oh; Hyung Jun Park; Kyong Jin Shin; Yoon-Ho Hong
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

7.  Changes in N-glycans of IgG4 and its relationship with the existence of hypocomplementemia and individual organ involvement in patients with IgG4-related disease.

Authors:  Naoki Konno; Mitsuru Sugimoto; Tadayuki Takagi; Makiko Furuya; Tomoyuki Asano; Shuzo Sato; Hiroko Kobayashi; Kiyoshi Migita; Yoshiaki Miura; Taichi Aihara; Atsushi Komatsuda; Hiromasa Ohira; Hiroshi Watanabe
Journal:  PLoS One       Date:  2018-04-19       Impact factor: 3.240

8.  Autoantibody of NRIP, a novel AChR-interacting protein, plays a detrimental role in myasthenia gravis.

Authors:  Li-Kai Tsai; I-Hsin Chen; Chi-Chao Chao; Hsueh-Wen Hsueh; Hsin-Hsiung Chen; Yun-Hsin Huang; Rong-Wei Weng; Tzu-Yun Lai; Yi-Chieh Tsai; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-03-26       Impact factor: 12.910

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.